![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
January 26, 2022
Mary Lou Smith and colleagues at the Research Advocacy Network recently explored how well patients with early-stage breast cancer understand risk of recurrence
January 26, 2022
This randomized phase 2 trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
December 22, 2021
This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
October 19, 2021
A focus on the Fall 2021 ECOG-ACRIN Group Meeting; remembering two major leaders in oncology; studying smoking cessation in patients with cancer
October 19, 2021
Though we had hoped to meet in person this fall, the pandemic has kept us on our toes—and in front of our screens.
October 19, 2021
Eight early-career investigators will present their work; two will be selected to receive awards of distinction
October 19, 2021
In September, the field of immunotherapy lost one of its pioneers
October 19, 2021
In September, the field of oncology lost a worldwide ovarian therapeutics leader and unparalleled mentor to generations
October 19, 2021
This phase II randomized controlled trial is comparing the effectiveness of two different approaches to help recently diagnosed patients with cancer become smoke-free
October 19, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
September 30, 2021
This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
September 30, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more